Ken Griffin Can Fite Bio Pharma Ltd. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.83 - $1.24 $9,406 - $14,052	-11,333 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.94 - $1.45 $10,653 - $16,432	11,333 New	11,333 $14,000
Q3 2021 Nov 15, 2021	SELL	$1.65 - $2.34 $63,727 - $90,377	-38,623 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.97 - $2.48 $42,264 - $53,205	-21,454 Reduced 35.71%	38,623 $88,000
Q1 2021 May 17, 2021	BUY	$1.8 - $2.92 $108,138 - $175,424	60,077 New	60,077 $148,000

Q4 2020 Feb 16, 2021	SELL	$1.66 - $2.15 $19,707 - $25,524	-11,872 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$1.61 - $2.67 $19,113 - $31,698	11,872 New	11,872 $21,000
Q2 2020 Aug 14, 2020	SELL	$1.28 - $2.5 $25,762 - $50,317	-20,127 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.13 - $3.52 $22,743 - $70,847	20,127 New	20,127 $26,000
Q4 2019 Feb 14, 2020	SELL	$1.95 - $4.4 $45,167 - $101,917	-23,163 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.06 - $3.3 $47,715 - $76,437	23,163 New	23,163 $47,000

1.1K

Ticker CANF
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,191,500
Market Cap $77.2M
Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinic...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.